Related Experiment Video
Updated: Dec 9, 2025

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa
1Department of Dermatology, SBMP Medical College Hospital & Research Center, BLDE University, Vijaypura, Karnataka, India.
Insights
Losartan treatment reduced blistering and improved quality of life in a child with recessive dystrophic epidermolysis bullosa (RDEB). This study highlights losartan as a potential therapy for RDEB symptoms.
Area of Science:
- Dermatology
- Genetics
- Pharmacology
Background:
- Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic skin disorder.
- RDEB is characterized by extreme skin fragility and blistering.
- Current treatments for RDEB are limited and primarily supportive.
Abstract:
A 6-year-old child with recessive dystrophic epidermolysis bullosa, confirmed by history, clinical exam, and antigen mapping, was treated with losartan with reduction in the blistering and better quality of life.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Aortic Regurgitation III: Medical Management

